Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 7.

Lear, J T; Migden, M R; Lewis, K D; Chang, A L S; Guminski, A; Gutzmer, R; Dirix, L; Combemale, P; Stratigos, A; Plummer, R; Castro, H; Yi, T; Mone, M; Zhou, J; Trefzer, U; Kaatz, M; Loquai, C; Kudchadkar, R; Sellami, D; Dummer, R (2018). Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. Journal of the European Academy of Dermatology and Venerology, 32(3):372-381.

Mohr, P; Hauschild, A; Trefzer, U; Enk, A; Tilgen, W; Loquai, C; Gogas, H; Haalck, T; Koller, J; Dummer, R; Gutzmer, R; Brockmeyer, N; Holzle, E; Sunderkotter, C; Mauch, C; Stein, A; Schneider, L A; Podda, M; Goppner, D; Schadendorf, D; Weichenthal, M (2015). Intermittent high-dose intravenous interferon Alfa-2b for adjuvant treatment of stage III melanoma: Final analysis of a randomized phase III dermatologic cooperative oncology group trial. Journal of Clinical Oncology, 33(34):4077-4084.

Schilling, B; Sondermann, W; Zhao, F; Griewank, K G; Livingstone, E; Sucker, A; Zelba, H; Weide, B; Trefzer, U; Wilhelm, T; Loquai, C; Berking, C; Hassel, J; Kähler, K C; Utikal, J; Al Ghazal, P; Gutzmer, R; Goldinger, S M; Zimmer, L; Paschen, A; Hillen, U; Schadendorf, D; Dermatologic Cooperative Oncology Group (2014). Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology, 25(3):747-753.

Schadendorf, D; Amonkar, M M; Milhem, M; Grotzinger, K; Demidov, L V; Rutkowski, P; Garbe, C; Dummer, R; Hassel, J C; Wolter, P; Mohr, P; Trefzer, U; Lefeuvre-Plesse, C; Rutten, A; Steven, N; Ullenhag, G; Sherman, L; Wu, F S; Patel, K; Casey, M; Robert, C (2014). Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Annals of Oncology, 25(3):700-706.

Flaherty, K T; Robert, C; Hersey, P; Nathan, P; Garbe, C; Milhem, M; Demidov, L V; Hassel, J C; Rutkowski, P; Mohr, P; Dummer, R; Trefzer, U; Larkin, J; Utikal, J; Dreno, B; Casey, M; Sherman, L J; Wu, F S; Schadendorf, D (2012). Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group. New England Journal of Medicine, 367(2):107-114.

Patel, P M; Suciu, S; Mortier, L; Kruit, W H; Robert, C; Schadendorf, D; Trefzer, U; Punt, C J A; Dummer, R; Davidson, N; Becker, Juergen; Conry, R; Thompson, J A; Hwu, W J; Engelen, K; Agarwala, S S; Keilholz, U; Eggermont, A M M; Spatz, A (2011). Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). European Journal of Cancer, 47(10):1476-1483.

Speiser, D E; Schwarz, K; Baumgaertner, P; Conzett, K B; Manolova, V; Devevre, E; Sterry, W; Walden, P; Zippelius, A; Senti, G; Voelter, V; Cerottini, J P; Guggisberg, D; Willers, J; Geldhof, C; Romero, P; Kündig, T; Knuth, A; Dummer, R; Trefzer, U; Bachmann, M F (2010). Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Journal of Immunotherapy, 33(8):848-858.

This list was generated on Wed Mar 20 23:12:04 2019 CET.